Combination therapy was not superior to monotherapy. The addition of meropenem tocolistin did not improve clinical failure in severe A baumannii infections. The trialwas unpowered to specifically address other bacteria.

Fonte: Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial – The Lancet Infectious Diseases